We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Heart transplantation remains the only realistic therapeutic option for children with end-stage heart disease. The main indication for transplantation in children is severe heart failure (HF) associated with impaired function of the systemic ventricle. Extensive evidence supports the use of cardiopulmonary exercise testing to select patients with increased short-term mortality who should be offered transplantation. Transplantation for congenital heart disease illustrates best many of the peculiarities of heart transplant in the pediatric age group. The assessment of pulmonary vascular resistance (PVR) is particularly crucial in order to reduce the rate of right HF post-transplant, but it can be technically difficult, particularly in congenital heart disease. Maintenance therapy is commonly a combination of a calcineurin inhibitor (CNI) and cell cycle inhibitor. A problem in pediatric transplantation is the presence of pre-existing human leukocyte antigen (HLA) antibodies, which have been linked to increased hyperacute, cellular, and humoral rejection and increased mortality posttransplant.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.